In 1998, Dr. Odidi co-founded Intellipharmaceutics Inc., the predecessor of publicly-traded Intellipharmaceutics International Inc. From 1995 to 1998, Dr. Odidi held positions, first as Director, then as Vice President of Research of Drug Development and New Technologies, at Biovail Corporation International, (now Valeant Pharmaceutical International, Inc.),  a drug delivery company.

Prior to 1995, Dr. Odidi held several senior positions in academia and in the pharmaceutical and health care industries. His work has been cited in textbooks and he has published over a hundred scientific and medical papers, articles, and textbooks.

He currently holds a Chair as Professor of Pharmaceutical Technology at the Toronto Institute of Pharmaceutical Technology in Canada, and is an Adjunct Professor at the Institute for Molecular Medicine in California.

Dr. Odidi received his B.Sc. Pharmacy (Ahmadu Bello University, Nigeria), M.Sc.  Pharmaceutical Technology, Ph.D. Pharmaceutics (University of London), and MBA (Joseph L. Rotman School of Management, University of Toronto), is also a graduate of the Western Executive Program, Ivey School of Business (University of Western Ontario). Dr. Odidi recently awarded Honorary Doctor of Science degree (Honoris causa) University of Benin, Nigeria.  

In 1998, Dr. Amina Odidi co-founded Intellipharmaceutics Inc., the predecessor of publicly-traded Intellipharmaceutics International Inc. She has been President, COO, and Co-Chief Scientist since 1998. Dr. Amina Odidi has extensive experience developing and applying proprietary technologies to the development of controlled-release drug products for third-party pharmaceutical companies. She has invented or co-invented various proprietary controlled delivery devices for the delivery of pharmaceutical, nutriceutical, biological, agricultural and chemical agents. Previously she has worked for the pharmaceutical and health care industry. She has co-authored 8 articles, papers and textbooks. She received her B.Sc. in Pharmacy, M.S. in Biopharmaceutics, and her Ph.D. in Pharmaceutics from the University of London.

Mr. Allport has been Vice President, Licensing and Legal since 2005. He was Director of Technology Licensing from 2001 to 2004. Mr. Allport has in excess of twenty years' experience in the field of intellectual property law as a litigator with the international IP firm Sim Lowman Ashton & McKay LLP of Toronto, acting for and against many Fortune 500 companies. In that position, he also assisted in the creation and exploitation of the extensive IP licensing interests of such international licensing giants as Walt Disney Corporation, the Canadian Olympic Association and the World Wildlife Fund.

Dr. Yat has been has been Vice President at Intellipharmaceutics since 2005 and has been involved in the pharmaceutical or pharmaceutical related industry since 1992 when he worked at Health Canada as Visiting Scientist. Previously, he worked at Patheon Inc., where he was instrumental in the successful take off of its pre-formulation unit. He also served with Biovail Corporation where he was involved in methods development and validation of the company's pipeline products as well as heading the pre-formulation activity for the company. Dr. Yat currently sits as an expert committee member of the USP on methods development and is on the advisory board of the Toronto Institute of Pharmaceutical Technology on QC program. Dr. Yat received his Ph.D. from the University of Salford, U.K. His Ph.D. research on Opoid analgesics was supported by industry.

Mr. Rampertab joined Intellipharmaceutics in December 2010. He is a chartered accountant (CA) since 1994, brings public company experience to Intellipharmaceutics, having previously served as the Director, Finance and Secretary-Treasurer for then-public Drug Royalty Corp. Mr. Rampertab also served as health sciences and biotechnology analyst at several investment banking firms including Canaccord Capital, and was until recently a Partner, Healthcare Investment Banking at Loewen Ondaatje McCutcheon Limited, where he specialized in raising equity funds for life-science companies. He received an MBA from McMaster University and a BSc. from the University of Toronto and has substantial expertise with licensing and royalty deals. Mr. Rampertab is currently Chairman of the Board of Imaging Dynamics Company Ltd. (TSX: IDL).